SMMT Summit Therapeutics plc

11.40
+1  (5%)
Previous Close 10.87
Open 11.07
Price To book 0.00
Market Cap 141.11M
Shares 12,378,000
Volume 5,671
Short Ratio 3.25
Av. Daily Volume 15,618

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
Ridinilazole
C. difficile infection (CDI)
Phase 2 24-week data due 1Q 2018.
Ezutromid
Duchenne muscular dystrophy

Latest News

  1. Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
  2. Summit Therapeutics Plc :SMMT-US: Earnings Analysis: Q4, 2017 By the Numbers : April 4, 2017
  3. Summit Therapeutics to Present at the Needham Healthcare Conference
  4. Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
  5. Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMD
  6. Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017
  7. Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
  8. Glaxo Files for Label Expansion of Influenza Vaccine in US
  9. Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
  10. Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
  11. J&J Presents Positive Phase III Data on Psoriasis Candidate
  12. Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat
  13. Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data
  14. Summit Therapeutics Recognises 10th Annual Rare Disease Day
  15. How the state’s newest Duchenne biotechs are getting a boost from patient groups
  16. BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
  17. Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
  18. Congressman Keating calls pricy Duchenne drug an example of 'gouging'
  19. Santhera opens Mass. office as local Duchenne ecosystem grows
  20. Summit Therapeutics to Participate in February Investor Conferences